Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

September 20, 2016 updated by: GlaxoSmithKline

Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life

This is a study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals live attenuated measles-mumps-rubella-varicella vaccine given to healthy children in their second year of life.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

1439

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Finland
      • Espoo, Finland, 02100
        • GSK Investigational Site
      • Lahti, Finland, 15140
        • GSK Investigational Site
      • Oulu, Finland, 90100
        • GSK Investigational Site
      • Pori, Finland, 28120
        • GSK Investigational Site
      • Tampere, Finland, 33200
        • GSK Investigational Site
      • Turku, Finland, 20520
        • GSK Investigational Site
      • Vantaa, Finland, 01300
        • GSK Investigational Site
  • Germany
    • Bayern
      • Bayreuth, Bayern, Germany, 95444
        • GSK Investigational Site
      • Bindlach, Bayern, Germany, 95463
        • GSK Investigational Site
      • Bobingen, Bayern, Germany, 86399
        • GSK Investigational Site
      • Cham, Bayern, Germany, 93413
        • GSK Investigational Site
      • Kempten, Bayern, Germany, 87435
        • GSK Investigational Site
      • Muenchen, Bayern, Germany, 81735
        • GSK Investigational Site
      • Muenchen, Bayern, Germany, 81241
        • GSK Investigational Site
      • Noerdlingen, Bayern, Germany, 86720
        • GSK Investigational Site
      • Nuernberg, Bayern, Germany, 90473
        • GSK Investigational Site
      • Olching, Bayern, Germany, 82140
        • GSK Investigational Site
      • Tegernsee, Bayern, Germany, 83684
        • GSK Investigational Site
      • Tutzing, Bayern, Germany, 82327
        • GSK Investigational Site
      • Veitshoechheim, Bayern, Germany, 97209
        • GSK Investigational Site
    • Hessen
      • Eschwege, Hessen, Germany, 37269
        • GSK Investigational Site
      • Frankfurt, Hessen, Germany, 60389
        • GSK Investigational Site
      • Fulda, Hessen, Germany, 36037
        • GSK Investigational Site
      • Nidderau, Hessen, Germany, 61130
        • GSK Investigational Site
      • Wiesbaden, Hessen, Germany, 65205
        • GSK Investigational Site
    • Niedersachsen
      • Salzgitter, Niedersachsen, Germany, 38226
        • GSK Investigational Site
      • Wolfenbuettel, Niedersachsen, Germany, 38302
        • GSK Investigational Site
    • Nordrhein-Westfalen
      • Bad Oeynhausen, Nordrhein-Westfalen, Germany, 32549
        • GSK Investigational Site
      • Bochum, Nordrhein-Westfalen, Germany, 44866
        • GSK Investigational Site
      • Detmold, Nordrhein-Westfalen, Germany, 32756
        • GSK Investigational Site
      • Dortmund, Nordrhein-Westfalen, Germany, 44329
        • GSK Investigational Site
      • Espelkamp, Nordrhein-Westfalen, Germany, 32339
        • GSK Investigational Site
      • Goch, Nordrhein-Westfalen, Germany, 47574
        • GSK Investigational Site
      • Guetersloh, Nordrhein-Westfalen, Germany, 33332
        • GSK Investigational Site
      • Hille, Nordrhein-Westfalen, Germany, 32479
        • GSK Investigational Site
      • Kirchlengern, Nordrhein-Westfalen, Germany, 32278
        • GSK Investigational Site
      • Krefeld, Nordrhein-Westfalen, Germany, 47798
        • GSK Investigational Site
      • Loehne, Nordrhein-Westfalen, Germany, 32584
        • GSK Investigational Site
      • Minden, Nordrhein-Westfalen, Germany, 32427
        • GSK Investigational Site
      • Moenchengladbach, Nordrhein-Westfalen, Germany, 41061
        • GSK Investigational Site
      • Moenchengladbach, Nordrhein-Westfalen, Germany, 41236
        • GSK Investigational Site
      • Muenster, Nordrhein-Westfalen, Germany, 48159
        • GSK Investigational Site
      • Wesseling, Nordrhein-Westfalen, Germany, 50389
        • GSK Investigational Site
      • Willich, Nordrhein-Westfalen, Germany, 47877
        • GSK Investigational Site
  • Greece
      • Arta, Greece, 471 00
        • GSK Investigational Site
      • Athens, Greece, 11527
        • GSK Investigational Site
      • Komotini, Greece, 69100
        • GSK Investigational Site
      • Rhodes, Greece, 851 00
        • GSK Investigational Site
      • Thessaloniki, Greece, 54636
        • GSK Investigational Site
  • Poland
      • Bydgoszcz, Poland, 85-021
        • GSK Investigational Site
      • Krakow, Poland, 31-202
        • GSK Investigational Site
      • Poznan, Poland, 61-709
        • GSK Investigational Site
      • Siemianowice Slaskie, Poland, 41-103
        • GSK Investigational Site
      • Trzebnica, Poland, 55-100
        • GSK Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

11 months to 1 year (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • A male or female subject between 11-13 months of age (i.e. from 11 month birthday until the day before the 14 month birthday) at the time of the first vaccination.

Exclusion Criteria:

  • History of previous measles, mumps, rubella and/or varicella vaccination or disease, or known exposure to any of these diseases within 30 days prior to the start of the trial
  • Planned administration of a vaccine not foreseen by the study protocol from 30 days prior to each vaccination until 42-56 days after each vaccination

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Antibody levels after vaccination.

Secondary Outcome Measures

Outcome Measure
Safety of the study vaccines.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

GlaxoSmithKline

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2005

Primary Completion (Actual)

November 1, 2005

Study Completion (Actual)

November 1, 2005

Study Registration Dates

First Submitted

August 4, 2005

First Submitted That Met QC Criteria

August 4, 2005

First Posted (Estimate)

August 5, 2005

Study Record Updates

Last Update Posted (Estimate)

September 21, 2016

Last Update Submitted That Met QC Criteria

September 20, 2016

Last Verified

September 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 104020

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Study Data/Documents

  1. Dataset Specification
    Information identifier: 104020
    Information comments: For additional information about this study please refer to the GSK Clinical Study Register
  2. Clinical Study Report
    Information identifier: 104020
    Information comments: For additional information about this study please refer to the GSK Clinical Study Register
  3. Study Protocol
    Information identifier: 104020
    Information comments: For additional information about this study please refer to the GSK Clinical Study Register
  4. Individual Participant Data Set
    Information identifier: 104020
    Information comments: For additional information about this study please refer to the GSK Clinical Study Register
  5. Informed Consent Form
    Information identifier: 104020
    Information comments: For additional information about this study please refer to the GSK Clinical Study Register
  6. Statistical Analysis Plan
    Information identifier: 104020
    Information comments: For additional information about this study please refer to the GSK Clinical Study Register

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Measles

Clinical Trials on Measles, Mumps, Rubella and Chickenpox (live vaccine)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe